Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32673424 | 0.81 | NOTUM (0.62) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL27178980 | 0.80 | NOTUM (0.48) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL31404143 | 0.80 | NOTUM (0.48) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL21173009 | 0.78 | NOTUM (0.49) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL21172566 | 0.78 | NOTUM (0.49) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL26818531 | 0.77 | NOTUM (0.48) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL1760504 | 0.77 | NOTUM (0.48) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL31404147 | 0.77 | NOTUM (0.48) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL1760583 | 0.76 | NOTUM (0.50) | NOTUMALDH1A1HTTNPC1RAB9A | |
| SCHEMBL21172617 | 0.74 | ALDH1A1 (0.46) | NOTUMALDH1A1HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522582-B2 | Antiviral indolinyl compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101529-A1 | ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF | MAVS, IRF3, EIF2AK2 | NOTUM 1450/4885ALDH1A1 2480/4885HTT 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.